Michael LeBlanc

Also affiliated with SWOG Cancer Research Network

MedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 33 papers. Top paper: “Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma”.

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2405888

N/A

3.4DataRank · unranked

211 citations

Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens +42 more

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

Journal of Geriatric Oncology(2021)10.1016/j.jgo.2021.10.003

N/A

0.736DataRank · unranked

24 citations

Hongli Li, Anne Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh +9 more

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Hematological Oncology(2023)10.1002/hon.3163_5

N/A

0.464DataRank · unranked

21 citations

Michael LeBlanc, Sharon M. Castellino, Huilin Li, Sarah C. Rutherford, Andrew M. Evens +41 more

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad003

N/A

0.330DataRank · unranked

8 citations

Qian Lu, Mary W. Redman, Susan S. Tavernier, Lori M. Minasian, Ellen V. Sigal +17 more

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00813-3

N/A

0.241DataRank · unranked

4 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0029

N/A

0.104DataRank · unranked

1 citations

Xing Hua, Khaled Tolba, David Fabrizio, Lee A. Albacker, Ryan Brennick +11 more

Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial

Haematologica(2025)10.3324/haematol.2025.288057

N/A

0.104DataRank · unranked

1 citations

Hongli Li, Mazyar Shadman, Lisa M. Rimsza, Ahmad S. Zebari, Sonali M. Smith +5 more

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8038

N/A

0.104DataRank · unranked

1 citations

Jun Yin, Levi Pederson, Betsy LaPlant, Mazyar Shadman, Hongli Li +15 more

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Blood Advances(2023)10.1182/bloodadvances.2022009467

N/A

0DataRank · unranked

14 citations

Hongli Li, Diana G. Adlowitz, Janice M. Spence, Lisa M. Rimsza, Mazyar Shadman +7 more

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European Urology(2023)10.1016/j.eururo.2023.03.036

N/A

0DataRank · unranked

10 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +11 more

A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016

Hematological Oncology(2023)10.1002/hon.3163_79

N/A

0DataRank · unranked

2 citations

H. Li, Lisa M. Rimsza, John P. Leonard, Mark Kaminski, Catherine Spier +6 more

Risk prediction of hepatitis B or C or HIV among newly diagnosed cancer patients

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad053

N/A

0DataRank · unranked

1 citations

Cathee Till, Jessica Hwang, Kathryn B. Arnold, Michael LeBlanc, Dawn L. Hershman +2 more

S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL

Hematological Oncology(2023)10.1002/hon.3166_ot22

N/A

0DataRank · unranked

1 citations

Patrick M. Reagan, H. Li, Hayder Saeed, Riha Vaidya, Joseph M. Unger +5 more

Augmented Learning of Heterogeneous Treatment Effects via Gradient Boosting Trees

arXiv (Cornell University)(2023)10.48550/arxiv.2302.01367

N/A

0DataRank · unranked

0 citations

Michael LeBlanc, James Y. Dai, Heng Chen

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5048

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Association of measures of socioeconomic deprivation with healthcare utilization in elderly patients enrolled in SWOG cancer clinical trials.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6527

N/A

0DataRank · unranked

0 citations

Riha Vaidya, Cathee Till, William E. Barlow, Michael LeBlanc, Scott D. Ramsey +2 more

Estimating individualized treatment rules by optimizing the adjusted probability of a longer survival

Statistical Methods in Medical Research(2024)10.1177/09622802241262525

N/A

0DataRank · unranked

1 citations

Shixiao Zhang, Michael LeBlanc, Ying‐Qi Zhao, Qijia He

Title Pending 371

Journal of the Society for Clinical Data Management(2024)10.47912/jscdm.371

N/A

0DataRank · unranked

1 citations

Chris Cook, Dani Weatherbee, Sunita Yadav, Dinesh Pal Mudaranthakam, Rachael Sexton +14 more

The cost of doing business: Drug costs in federally sponsored cancer clinical trials.

JCO Oncology Practice(2024)10.1200/op.2024.20.10_suppl.10

N/A

0DataRank · unranked

2 citations

Hong Xiao, Riha Vaidya, Sara Ashley Threlkel, Matthew Chansky, Allison Hayes +3 more

Reverse Selection Designs for Accommodating Multiple Control Arms

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1282

N/A

0DataRank · unranked

0 citations

Megan Othus, Michael LeBlanc, Michael C. Wu, Sarah Samorodnitsky

21 | PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN PATIENTS WITH ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED ON SWOG S1826

Hematological Oncology(2025)10.1002/hon.70093_21

N/A

0DataRank · unranked

4 citations

Marcin Kaszkowiak, Michael LeBlanc, Chip Stewart, Alex F. Herrera, J Castillo +18 more

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials

Clinical Trials(2025)10.1177/17407745241304065

N/A

0DataRank · unranked

2 citations

Michael LeBlanc, Boris Freidlin, Rory M. Shallis, Amer M. Zeidan, David A. Sallman +4 more

20 | IMPACT OF EBV STATUS AND HISTOLOGY ON OUTCOMES WITH NIVOLUMAB‐AVD VERSUS Bv‐AVD IN PATIENTS ENROLLED ON SWOG S1826

Hematological Oncology(2025)10.1002/hon.70093_20

N/A

0DataRank · unranked

1 citations

H. Li, Alex F. Herrera, Anamarija M. Perry, Alexandra E. Kovach, Kelly Davison +13 more

127 | HEALTH‐RELATED QUALITY OF LIFE (HRQoL) ENDPOINTS OF THE PHASE III INTERGROUP S1826 ADVANCED‐STAGE, CLASSIC HODGKIN LYMPHOMA (cHL) TRIAL

Hematological Oncology(2025)10.1002/hon.70093_127

N/A

0DataRank · unranked

1 citations

H. Li, Alex F. Herrera, Kelly Davison, Sharon M. Castellino, Hildy Dillon +11 more

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

The Lancet Oncology(2020)10.1016/s1470-2045(20)30475-7

N/A

0DataRank · unranked

125 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +21 more

Composition of health care contact days and mortality prediction among trial participants.

JCO Oncology Practice(2025)10.1200/op.2025.21.10_suppl.454

N/A

0DataRank · unranked

0 citations

Cathee Till, Michael LeBlanc, Dawn L. Hershman, Joseph M. Unger, Arjun Gupta

Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.3842

N/A

0DataRank · unranked

48 citations

Charles D. Blanke, Michael LeBlanc, William E. Barlow, Riha Vaidya, Scott D. Ramsey +2 more

An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps8067

N/A

0DataRank · unranked

8 citations

Michael LeBlanc, Alex F. Herrera, Susan K. Parsons, Angela Punnett, David Hodgson +8 more

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9576

N/A

0DataRank · unranked

2 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, David R. Gandara, Fred R. Hirsch, Philip C. Mack +14 more

Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic

JAMA Network Open(2021)10.1001/jamanetworkopen.2021.18433

N/A

0DataRank · unranked

55 citations

Hong Xiao, Michael LeBlanc, Dawn L. Hershman, Charles D. Blanke, Joseph M. Unger

Restricted survival benefit with right‐censored data

Biometrical Journal(2021)10.1002/bimj.202000392

N/A

0DataRank · unranked

4 citations

Michael LeBlanc, Ying‐Qi Zhao, Shixiao Zhang

Survival outcomes by insurance status for patients with cancer ages 18-64 and 65 or older treated in clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.28_suppl.154

N/A

0DataRank · unranked

1 citations

Anna Moseley, Riha Vaidya, Hong Xiao, Michael LeBlanc, Dawn L. Hershman +1 more

Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6543

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Qian Lü, Katherine Minichiello, Roy S. Herbst, David R. Gandara +14 more